Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Geriatric MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Behavioral and psychological symptoms in dementia.in: StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL)2022 (Accessed December 20, 2021)
- Association between polypharmacy and death: a systematic review and meta-analysis.J Am Pharm Assoc (2003). 2017; 57: 729-738.e10
- Polypharmacy correlates with increased risk for hip fracture in the elderly: a population-based study.Medicine (Baltimore). 2010; 89: 295-299
- Prevalence of central nervous system-active polypharmacy among older adults with dementia in the US.JAMA. 2021; 325: 952-961
- Polypharmacy and potentially inappropriate medication use among community-dwelling elders with dementia.Alzheimer Dis Assoc Disord. 2010; 24: 56-63
- Health outcomes associated with polypharmacy in community-dwelling older adults: a systematic review.J Am Geriatr Soc. 2014; 62: 2261-2272
- Best practice in the management of behavioural and psychological symptoms of dementia.Ther Adv Neurol Disord. 2017; 10: 297-309
- Interventions to reduce inappropriate prescribing of antipsychotic medications in people with dementia resident in care homes: a systematic review.J Am Med Dir Assoc. 2014; 15: 706-718
- Systematic review of recent dementia practice guidelines.Age Ageing. 2015; 44: 25-33
- The American psychiatric association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia.Am J Psychiatry. 2016; 173: 543-546
- Dementia: assessment, management and support for people living with dementia and their carers.(Available at:) (Accessed January 14, 2021)
- Canadian consensus conference on the diagnosis and treatment of dementia. fourth canadian consensus conference on the diagnosis and treatment of dementia: recommendations for family physicians.Can Fam Physician. 2014; 60: 433-438
- Clinical practice guidelines for dementia in Australia.Med J Aust. 2016; 204: 191-193
- Approaches to deprescribing psychotropic medications for changed behaviours in long-term care residents living with dementia.Drugs Aging. 2019; 36: 125-136
- Antipsychotics in the management of behavioral and psychological symptoms of dementia: maximizing gain and minimizing harm.Neurodegener Dis Manag. 2020; 10: 5-8
- Management of behavioral and psychological symptoms of dementia.Curr Psychiatry Rep. 2019; 21 (Published 2019 Jul 1): 66
- Treatment of senile agitation with chlorpromazine.Geriatrics. 1955; 10: 520-522
- The use of risperidone in behavioral and psychological symptoms of dementia: a review of pharmacology, clinical evidence, regulatory approvals, and off-label use.Front Pharmacol. 2020; 11 (Published 2020 May 20): 596
- New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer's disease: focus on brexpiprazole and pimavanserin.F1000Res. 2020; 9 (Faculty Rev-686): F1000https://doi.org/10.12688/f1000research.22662.1
- Off-label use of atypical antipsychotics: an update. Comparative Effectiveness Review No. 43. (Prepared by the Southern California Evidence-based Practice Center under Contract No. HHSA290-2007-10062- 1.).Agency for Healthcare Research and Quality, Rockville, MD2011 (Available at:)
- Deprescribing antipsychotics for behavioural and psychological symptoms of dementia and insomnia: evidence-based clinical practice guideline.Can Fam Physician. 2018; 64: 17-27
- Considerations in psychotropic treatments in dementia--can polypharmacy be avoided?.Int J Neuropsychopharmacol. 2014; 17: 1107-1117
- Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.N Engl J Med. 2006; 355: 1525-1538
- Antipsychotic use in dementia: a systematic review of benefits and risks from meta-analyses.Ther Adv Chronic Dis. 2016; 7: 229-245
- Assessment of reported comparative effectiveness and safety of atypical antipsychotics in the treatment of behavioral and psychological symptoms of dementia: a network meta-analysis.JAMA Netw Open. 2019; 2 (Published 2019 Mar 1): e190828
- Pharmacologic management of behavioral and psychological symptoms of major neurocognitive disorder.Ment Health Clin. 2018; 8 (Published 2018 Nov 1): 284-293
- Early improvements of individual symptoms with antipsychotics predict subsequent treatment response of neuropsychiatric symptoms in alzheimer's disease: a re-analysis of the CATIE-AD study.J Clin Psychiatry. 2020; 81 (Published 2020 Feb 11): 19m12961
- Public health advisory: deaths with antipsychotics in elderly patients with behavioral disturbances.(Available at:) (Accessed December 10, 2021)
- Information for healthcare professionals: conventional antipsychotics.(Available at:) (Accessed December 10, 2021)
- The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial.Lancet Neurol. 2009; 8: 151-157
- Approaches to gradual dose reduction of chronic off-label antipsychotics used for behavioral and psychological symptoms of dementia.Consult Pharm. 2015; 30: 599-611
- Neuroleptic malignant syndrome: a review for neurohospitalists.Neurohospitalist. 2011; 1: 41-47
- Clinical and pharmacological risk factors for neuroleptic malignant syndrome : a case control study.Biol Psychiatry. 1998; 44: 748-754
- The evaluation and management of patients with neuroleptic malignant syndrome.Neurol Clin. 2004; 22: 389-411
- Risk factors for neuroleptic malignant syndrome: a case-control study.Arch Gen Psychiatry. 1989; 46: 914-918
- Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial.JAMA. 2014; 311: 682-691
- R- and S-citalopram concentrations have differential effects on neuropsychiatric scores in elders with dementia and agitation.Br J Clin Pharmacol. 2016; 82: 784-792
- What is the therapeutic value of antidepressants in dementia? A narrative review.Int J Geriatr Psychiatry. 2017; 32: 32-49
- Management of behavioral and psychological symptoms in people with Alzheimer's disease: an international Delphi consensus.Int Psychogeriatr. 2019; 31: 83-90
- Psychotropic drugs use and psychotropic polypharmacy among persons with Alzheimer's disease.Eur Neuropsychopharmacol. 2018; 28: 1260-1269
- Withdrawal versus continuation of long-term antipsychotic drug use for behavioural and psychological symptoms in older people with dementia [published online ahead of print, 2018 Mar 30].Cochrane Database Syst Rev. 2018; 3: CD007726
- Stopping antipsychotic drug therapy in demented nursing home patients: a randomized, placebo-controlled study--the Bergen District Nursing Home Study (BEDNURS).Int J Geriatr Psychiatry. 2008; 23: 889-895
- Antipsychotic deprescription for older adults in long-term care: the HALT study.J Am Med Dir Assoc. 2018; 19: 592-600.e7
- Deprescribing.org.(Available at:) (Accessed January 15, 2022)
- Deprescribing antipsychotics in long term care patients with dementia. Deprescribing antipsychotics in long term care patients with dementia.Farm Hosp. 2019; 43 (Published 2019 Jul 1): 140-145
Article info
Publication history
Published online: September 11, 2022
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
